Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326252 | 1.00 | CA1 (0.38) | CA1CA2TAS1R3TAS1R1POLB | |
| SCHEMBL2330257 | 0.88 | CA1 (0.38) | CA1CA2TAS1R3TAS1R1POLB | |
| SCHEMBL2330255 | 0.88 | CA1 (0.38) | CA1CA2TAS1R3TAS1R1POLB | |
| SCHEMBL2324298 | 0.85 | CHRM1 (0.36) | CA2POLBGPR84 | |
| SCHEMBL2324304 | 0.85 | CHRM1 (0.36) | CA2POLBGPR84 | |
| SCHEMBL2330262 | 0.85 | MGAM (0.36) | CA1CA2TAS1R3TAS1R1POLB | |
| SCHEMBL2330264 | 0.85 | MGAM (0.36) | CA1CA2TAS1R3TAS1R1POLB | |
| SCHEMBL23311196 | 0.83 | CA1 (0.33) | CA1CA2GPR84 | |
| SCHEMBL21602737 | 0.83 | CA1 (0.33) | CA1CA2GPR84 | |
| SCHEMBL21602746 | 0.83 | CA1 (0.33) | CA1CA2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | CA1 2079/4885CA2 1508/4885TAS1R3 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.